"Tivic hits enrolment target for vagus nerve stimulation trial" was originally created and published by Medical Device ...

Verdence Capital Advisors LLC grew its holdings in Boston Scientific Co. (NYSE:BSX – Free Report) by 4.3% in the 3rd quarter, ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Deep Brain Stimulator MarketThe global deep brain stimulator market, valued at USD 1308.0 Million in 2024, is projected to grow steadily, reaching USD  2772.1 billion by 2034. With an anticipated CAGR ...

On Wednesday, Boston Scientific Corporation (NYSE:BSX) released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe ...

Boston Scientific continues to work closely with the U.S. Food and Drug Administration on the regulatory strategy for approval of the ACURATE valve platform in the U.S. The ACURATE neo2 Aortic ...

Boston Scientific Corporation (NYSE ... supported by de novo implants and competitive replacements. Our pain franchise grew ...

Allay Therapeutics appointed new additions to its clinical and scientific advisory boards, according to an Oct. 24 news release. The clinical advisory board provides guidance on the company's ATX101 ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...